Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1077MR)

This product GTTS-WQ1077MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1077MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10231MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ14667MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ14255MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ12529MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ13776MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ3587MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ819MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ6745MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DS 992
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW